Immunomodulatory properties of soluble recombinant human CD58 (LFA-3) molecules.
The interaction between the E-rosette receptor (CD2) expressed on the cell surface of T lymphocytes and its natural ligand CD58 (LFA-3), a broadly distributed cell surface molecule, represents a potential target for immune modulation. To explore this possibility, we have expressed a soluble recombinant form of human CD58 which exerts potent biological effects in that it acts as a competitive inhibitor for cell surface CD58 in its binding to CD2 positive lymphocytes. Thus, recombinant CD58 blocks NK-mediated cytotoxicity, the mixed lymphocyte reaction, and the T lymphocyte adhesion to CD58 positive cells. In contrast, recombinant CD58 synergized with mitogenic CD2R monoclonal antibodies (anti-T11(2/3) or 9.1) in T cell triggering.
Albert-Wolf
M
M
Dept. Applied Immunology, German Cancer Research Center, Heidelberg, Germany.
Meuer
S C
SC
Wallich
R
R
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology* / Q000378:metabolism; D018801:CD2 Antigens; D018968:CD58 Antigens; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000378:metabolism; D011485:Protein Binding; D011971:Receptors, Immunologic / Q000276:immunology* / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D012995:Solubility; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018968:CD58 Antigens; D008562:Membrane Glycoproteins; D011971:Receptors, Immunologic; D011994:Recombinant Proteins